Assenagon Asset Management S.A. Buys 240,643 Shares of Myriad Genetics, Inc. $MYGN

Key Points

• Assenagon Asset Management S.A. increased its stake in Myriad Genetics, Inc. by 285.2% during the second quarter, acquiring a total of 325,030 shares valued at approximately $1.7 million.
• In total, institutional investors own 99.02% of Myriad Genetics, indicating strong institutional support for the company.
• Despite recent investments, shares of Myriad Genetics saw a 0.8% decline, trading at $7.70 with a market cap of $716.45 million.

Assenagon Asset Management S.A. increased its position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 285.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 325,030 shares of the company's stock after buying an additional 240,643 shares during the quarter. Assenagon Asset Management S.A. owned 0.35% of Myriad Genetics worth $1,726,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Myriad Genetics in the second quarter worth about $147,000. Pallas Capital Advisors LLC bought a new stake in shares of Myriad Genetics during the 2nd quarter valued at $57,000. Voya Investment Management LLC boosted its stake in Myriad Genetics by 51.9% during the first quarter. Voya Investment Management LLC now owns 72,572 shares of the company's stock worth $644,000 after acquiring an additional 24,790 shares in the last quarter. Inspire Investing LLC grew its holdings in Myriad Genetics by 39.4% in the first quarter. Inspire Investing LLC now owns 43,727 shares of the company's stock worth $388,000 after purchasing an additional 12,354 shares during the period. Finally, Jane Street Group LLC increased its stake in shares of Myriad Genetics by 1,076.9% during the first quarter. Jane Street Group LLC now owns 213,826 shares of the company's stock valued at $1,897,000 after purchasing an additional 195,658 shares in the last quarter. 99.02% of the stock is currently owned by institutional investors.

Myriad Genetics Stock Down 0.8%

Shares of MYGN opened at $7.70 on Friday. The stock has a market cap of $716.45 million, a P/E ratio of -1.80 and a beta of 1.93. The business's 50 day moving average price is $6.06 and its 200-day moving average price is $6.29. Myriad Genetics, Inc. has a 52 week low of $3.76 and a 52 week high of $27.55.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.